Acipimox
As of the edition of 20 October 2026, Acipimox is a small molecule: marketed; acts on HCAR2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Small molecule
- Brand name
- Olbetam
- Approvals on record
- 4 in 4 regions
- Holder of the most recent approval
- Pfizer
- Registered trials
- 15, 1 stopped early
- Disease areas
- Nutrition and metabolism; Hormones; Heart and blood vessels; Immune system; Infections; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HCAR2 | Hydroxycarboxylic acid receptor 2 | Q8TDS4 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 8 | 7 | 0 | 0 |
| Phase 1 | 2 | 1 | 1 | 0 |
| Phase 2 | 3 | 1 | 1 | 1 |
| Phase 3 | 2 | 2 | 0 | 0 |
| All trials | 15 |